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Abstract
Introduction: The aim of the IMPACT (IMProving Access to Clinical Trial data) Observatory is to assess the transformation of clinical trials (CT) re-
lated to the evolution of sharing of CT data. The objective of this study is to establish a baseline for monitoring CT data sharing by the Observatory.
Materials and methods: In this scoping review we searched for publications that address sharing, dissemination, transparency or reuse of CT data 
published prior to December 31st 2000. Two authors screened titles and abstracts of 1204 records received by Medline searches and added 47 publi-
cations from direct discovery. Four researchers extracted, coded, and analyzed the predefined information from 102 selected papers.
Results: We found a growing recognition of the importance of data sharing prior to 2001. However, there were numerous obstacles including the 
ambiguity of the concept of data sharing, the absence of specific terminology and the lack of an “open” culture. By the end of 2000, data, metadata, 
and evidence based medicine were defined. Data sharing, registries, databases and re-analyses of individual patient data (IPD) emerged. The use of 
systematic reviews and IPD meta-analysis in decision making was promoted. Most arguments for broader data sharing came from oncology, paedia-
trics, rare diseases, AIDS, pregnancy, perinatal medicine, and media reporting related scandals.
Conclusions: Our findings indicate that the year 2000 could be used as a baseline for monitoring the evolution of CT data sharing as basic prerequ-
isites were set in place, including greater understanding that CT data sharing is essential for decision making and the advancements of the Internet.
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A clinical trial (CT) is a prospective controlled or 
uncontrolled study evaluating the effects of one 
or more health-related interventions assigned to 
human participants. In this paper, we use the term 
data sharing to describe the practice of making 
data from primary research publicly available for 
reuse. Many different types of data may be shared, 
including raw or analyzable data set; metadata, or 
“data about the data” (e.g., protocol, statistical an-
alysis plan, and analytic code); and aggregate, 
summary-level data (e.g., summary-level results 
posted in registries, lay summaries, publications, 
and clinical study reports) (1). Raw data, partici-
pant-level data and individual-participant data 
(IPD) are unprocessed data from a clinical trial 
which come in their original form (before the in-
formation has been analyzed or statistically ma-
nipulated) in contrast to aggregate data. They 
could be records of original observations, mea-
surements, and health-related interventions, re-
searcher’s records on patients, medical charts, 
hospital records, lab notes, evaluations, data re-
corded by instruments, attending physician notes, 
etc. (2).
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Results from health research are often considered 
a public good, and data sharing seen as beneficial, 
particularly because the re-analysis of data is the 
basis of reproducible research, which can help 
better understand results of a trial and serve as the 
basis of pooling data from multiple trials, thus re-
vealing new information beyond information 
gained from any single study (3-5).
Also, CT data sharing has been identified as useful 
to explain disagreements between individual CTs 
and prevent biases (6-8).
The objective of the IMPACT (IMProving Access to 
Clinical Trial data) Observatory is to assess the tran-
sition of clinical trials regarding data sharing due 
to ongoing initiatives, identify facilitators and bar-
riers of clinical trials data sharing, indicate trends, 
and inform the process (9,10). As we needed to es-
tablish a baseline from which to start monitoring 
changes regarding data sharing we decided to 
perform a scoping review. Specifically, as one of 
IMPACT Observatory studies, this scoping review 
aims to explore to what extent CT data were 
shared prior to 2001 and to determine the appro-
priateness of setting the year 2000 as the baseline 
from which the IMPACT Observatory could start 
monitoring changes regarding data sharing (10).
Observatories or natural experiments are epidemi-
ological studies that assess the impact of one or 
more interventions that are not controlled by the 
observatory researcher(s) to inform the process 
and indicate trends (11,12). 
Materials and methods
We performed a scoping review of the literature. A 
scoping review is a method used to better under-
stand a phenomenon; it generally consists of map-
ping literature on a specific topic, and identifying 
key concepts, theories, and sources of evidence. It 
is particularly useful when a research question is 
broad and the goal is to identify qualitative rather 
than quantitative parameters (13,14). Literature 
searches were performed in Medline by two librar-
ians using 8 different search strategies that were 
developed jointly with one reviewer. Searches 
were performed with no language limitations 
using strategies to select articles published prior 
to 2001 (i.e. up to December 31st 2000).
A flowchart of the selection process is presented 
in Figure 1. The following (MESH) terms were used: 
“clinical trials as topic“, ”information dissemina-
tion“, ”information storage and retrieval“, ”access 
to information“, ”disclosure“, ”drug industry, 
policy“ and looking for specific terms including 
“clinical trials dissemination storage and retrieval“, 
”clinical trial, information dissemination“, ”dis-
semination policy“, ”clinical trial dissemination–
drug industry“, ”disclosure” that included “drug in-
dustry”, and “access” that included “databases” 
and “policy”.
These searches yielded 1204 records. After de-
duplication and exclusion of papers published 
after December 31st 2000, titles and abstracts (if 
available) were screened by one reviewer, and 
then cross-checked by another reviewer. Inclusion 
criteria were as follows: any article reporting or 
possibly reporting on CT data sharing, databases, 
registries, repositories, re-analysis and related 
practice and/or policies published prior to Decem-
ber 31st 2000.
We also included 47 papers identified through 
previous work which met our inclusion criteria. 
Two of the authors independently evaluated 129 
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full text records for final inclusion. Upon full text 
assessment, 27 records were excluded as they did 
not meet inclusion criteria, but described patient 
registries, or librarian research, or sharing data 
other than the ones from clinical trials. Most dis-
crepancies were solved by discussion; remaining 
disputes were resolved by the third author.
We analyzed a total of 102 full texts. Two of the au-
thors independently extracted relevant informa-
tion in a predefined Excel file (Microsoft, Red-
mond, USA). A different pair of authors eliminated 
duplicates and summarized the information. We 
analysed two groups of topics: one group of topics 
(headings) in the Excel were phenomena includ-
ing data sharing, database, registries, repository. 
The other group of topics (heading) were disease 
and/or patient groups and scandals related to data 
sharing. This group of headings was further ex-
panded to capture specific disease or patient 
groups, as the preliminary analysis indicated that 
they appeared multiple times and created the 
atmosphere or even directly called for data shar-
ing, for transparency.
All three authors coded the information for the fol-
lowing topics: data sharing, registry, databases, 
oncology, AIDS, pregnancy and perinatal medi-
cine, child health/rare diseases, adverse effects, re-
analysis, fraud/falsifications, scandals, individual 
patient/participant data (IPD), publication bias.
Results
In our analysis of the 102 selected papers, we iden-
tified 3 major concepts of interest: data sharing, 
registries and databases. Figure 2 illustrates that 
this discussion peaked in years 1986 and 1993, 
however, significant expansion in the volume of 
relevant literature occurred between 1998 and 
2000.
As can be seen on Figure 3, calls for data sharing 
came from several health areas, most frequently 
from oncology, followed by child health/rare dis-
eases, AIDS, and pregnancy and perinatal medi-
cine. The most frequent topic discussed was publi-
cation bias, including both underreporting and 
duplicate reporting.  
Figure 2. Number of records addressing data sharing, regis-
tries, and database in selected literature prior to December 31st 
2000
Figure 3. Data sharing by topic and health area in which data 
sharing is addressed in the literature published prior to Decem-
ber 31st 2000.
However, the terminology was very ill-defined. For 
example, the term “database” was used extensive-
ly but described the collection of very diverse rec-
ords, including bibliographic databases (PubMed, 
EMBASE, etc.). Also, different terms were used to 
describe similar activities or similar systems. The 
term “registry” was used for observational data-
bases, clinical registries, patient registries and dis-
ease oriented registries; “trial banks” were also 
called large population cohorts, administrative 
databases, electronic patient records systems, 
large-scale databases, and databases of hospital 
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was introduced to refer to a collection of data from 
CT protocols (17-22). The term “individual patient 
data” was used either to indicate data collected as 
a part of providing routine healthcare for an indi-
vidual patient, or data collected during a prospect-
ive clinical trial. The acronym IPD was used to indi-
cate the Individual Patient Data, while now, in case 
of clinical trial IPDs, it stands for Individual Partici-
pant Data (23,24).
We selected actions and events that had major im-
pact on the evolution of CT data sharing prior to 
2001 and presented them in Figure 4. These key 
milestones include the call for trial registration and 
the establishment of CT registries (International 
Standard Randomized Controlled Trial Number 
(ISRCTN) registry and Clinicaltrials.gov), IPD meta-
analyses, the onset of the Cochrane Collaboration 
and the Evidence Based Medicine (EBM) (19-22,24-
28). We also included Nancy Olivieri scandal as it 
influenced the practice of industry - academia 
functioning (29,30). 
We also selected highlights of discussion of the 
evolution of data sharing and presented them in 
the Table 1. These include citations of pros and 
cons arguments, as well as some actions like start-
ing of databases and studies using data from in-
dustry sources.
Figure 4. Key milestones of clinical trial data sharing prior to 2001. EBM – evidence based medicine. IPD – individual patient/partici-
pant data. 
As can be seen in the Table 1, the last two decades 
of 20th century are rich in actions and discussion 
regarding sharing and reuse of CT data. Related 
discussions considered both the advantages and 
disadvantages or risks of these practices.
In 1992 Chalmers et al. identified weaknesses in all 
stages that took place between research and prac-
tice, from design and conduct of clinical trials, to 
the use of their results in decision making (25). In 
1992, Pignon et al. published the first meta-analy-
sis in which raw data were used (24). The Evidence 
Based Medicine started to form (26-28). Several 
important reasons for sharing raw data were put 
forward in the literature: the inclusion of unpub-
lished data in meta-analyses could decrease publi-
cation bias, and improve the relevance of the 
question, the interpretation of results, and the de-
sign of future trials, as well as help avoid unneces-
sary duplication of research (24,25,31-33). 
During this period, it was acknowledged that more 
powerful analyses could be run, stratified by trials, 
including subgroup analyses made possible if IPD 
data were available (24). The importance of IPD 
meta-analysis to produce evidence, develop 
guidelines, and support decision-making was in-
creasingly discussed (23,24,34). 
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Table 1.  Highlights of discussion of data sharing evolution prior to December 31st 2000
Year Event or citation Reference
1982 Launch of the Physician Database Query - an online database that provides summaries of current 




1982 National Cancer Institute started a database of clinical trials and cancer treatment; summaries of 1100 
protocols were shared as of 1988, as well as contact details of participants - name(s), address(es), and 
telephone number(s)
(17)
1987 The launching of KIGS international outcomes research database of longitudinal data on growth 
hormone therapy in children and adults. Of note, individual physicians retain the right to use their 
patients’ data for their own research purposes
(18)
1992 „Freedom of access and the sharing of research results have, traditionally, been values of science... 
The objectivity, accuracy, and reliability of observations and data interpretation that science requires 
can be destroyed subtly by financial incentives and by institutional and personal pride... Sharing of 
information is seriously impeded because investigators are in competition with one another for the 
market. “
(39)
1993 “ ... Individual companies may accept the principle that data from their clinical trials are a public as well 
as a private resource that needs to be made available for review...The pressure of publicity may achieve 
something. “
(40)
1993 “Large datasets can yield worthwhile information... At present, manufacturers guard the results of their 
in-house studies: they must be persuaded to be more open. Patients and physicians should insist that data 
derived from their care be made available (with full confidentiality protected) for other physicians to draw 
on.”
(6)
1993 There are no clear-cut rules governing access by other scientists to clinical trials’ data. The notion of 
routine archiving of clinical trials’ data is still fairly new.
(41)
1994 “No one would expect investigators to publish their raw data.” (31)
1994 “Unlocking large datasets is not reliable in this respect and is certainly not cheap.” (38)
1995 Cochrane working group on meta-analysis using individual patient data issued „Practical methodology 
of meta-analyses (overviews) using updated individual patient data“
(23)
1996 „Trial and error are still the fundamentals of advancement...The key to the sensible handling of data is a 
careful interpretation of observed associations rather than the artificial erection of barriers. “
(8)
1998 Repository first mentioned as a term for a database that wold enable virtual clinical trials, by a “ 
comprehensive, integrated view of the diverse population cared for by the University of Pennsylvania 
Health System”.
(42)
1998 A group of authors of a meta-analysis contacted manufacturers regarding other unpublished and 
published randomized controlled trials,but the authors specified no other details.
(43)
1998 Individual studies from Abbott Laboratories’ clinical database are accessible for re-analysis. (44)
1998 „All trial evidence should be published before new drugs are marketed, and medical journals should 
not carry advertisements referring to unpublished data. “
(32)
1998 „Paramount in the new ethics of epidemiological research is concern for the place of individual 
informed consent to the disclosure and use of personal information maintained in proprietary 
databases, governmental registries, and medical records.“
(45)
1998 ISRCTN Clinical trial registry started. In response to the growing body of opinion in favor of prospective 
registration of randomized trials, the Science Navigation Group launched the CCT website in 1998 as 
the metaRegister of Controlled Trials, mRCT. In 2003 it added an unique ID to each trial and renamed it 
to ISRCTN. It is possible to cite a trial using this ID number.
(22)
1999 „Information about published and unpublished clinical trials should be ideally placed in a registry. 
Internet communication will be important mean of exchange of information.“ Stated R. Horton and R. 
Smith, editors of Lancet.
(37)
1999 Anonymised data (sociodemographic data without revealing a patient’s identity: employer and insurer 
names, race, ethnicity, and age) in the cancer outcome database.
(46)
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In 1995, the Cochrane Collaboration convened a 
workshop in London, UK, to discuss the practical-
ities of meta-analyses based on IPDs (23). As it be-
came clearer in 1996, that data could and should 
be reused, Michels and Rosner concluded that it is 
more important to raise awareness on sensible 
handling of data than to artificially erect the bar-
riers to data sharing (8). The importance of sharing 
raw data was further promoted by Vamvakas and 
Blajchman who noted that raw data meta-analysis 
could solve disagreements between individual 
randomised controlled trials (RCTs) (7).
During this decade, there also were breakthrough 
developments in the area of information technol-
ogy, both in terms of software and hardware, 
which provided the underlying means to store 
and manage information (35,36). The develop-
ment of the Internet was quickly recognized as an 
important tool for sharing growing corpus of in-
formation, such as raw data (33,37).
Discussion
Our scoping review reveals that CT data sharing in-
tensified during the last two decades of 20th cen-
tury, helping forge a strong consensus that a strict 
baseline could not be drawn, but the real deal 
breaker was using individual patient data in a me-
ta-analysis in 1992 (24). In this dynamic process a 
key terminology was defined, and new methodol-
ogies were pioneered. This process was led by the 
Cochrane Collaboration, which sought to improve 
the quality of systematic reviews and of the IPD 
meta-analysis, and developed and published 
methodological guidance for IPD meta-analysis 
(23). There was a broad discussion on the benefits 
of data sharing, often led by HIV/AIDS or cancer 
patient groups, as well as media reports related to 
the harmful consequences of not sharing of CT 
data. However, the growing consensus related to 
the value of data sharing was matched by numer-
ous obstacles including the lack of data sharing 
Year Event or citation Reference
1999 “The request to enroll and file a CRF will be sent to the clinical trials repository. The repository will 
interpret the request and generate a dynamic CRF for the user to fill out. Corrections will be completed at 
the time of filing, according to specifications in the repository, and the “clean” CRF will be returned to the 
repository.”
(47)
1999 The manufacturer (Pfizer) provided some unpublished information from clinical trials, mentioned as a 
reference „Data on file“
(48)
1999 A comprehensive data file of the manufacturer (no details) utilized to evaluate the clinical safety profile 
of a drug.
(49)
1999 Use of patient data from observational databases (EuroSIDA, the French Hospital Database on HIV and 
the Swiss HIV) to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of 
cohort studies with randomized trials.
(50)
2000 The manufacturer (Novo Nordisk) provided unpublished information, mentioned as a reference (Data on 
file).
(51)
2000 Large complex databases are available to scientists, information stored and can be tested using this 
well of knowledge
(33)
2000 ClinicalTrials.gov established in February 2000. Contained information about approximately 5000 trials. (20)
2000 „In January 2001, the United Kingdom will become the first place to offer public access to a database 
of all UK clinical trials on new medicines sponsored by the pharmaceutical industry“ announced the 
Association of British Pharmaceutical Industry (ABPI).
(52)
2000 „Now that electronic publication is possible there is no reason why every well-conducted clinical trial is 
not published.” Commented Iain Chalmers, director of the UK Cochrane centre.
(52)
NCI - National Cancer Institute. KIGS - Kabi Pharmacia & Upjohn International Growth Database. ISRCTN - International Standard 
Randomized Controlled Trial Number. CCT -Current Controlled Trials. CRF - Case Report Form. EuroSIDA - Pan-European 
Observational Study of HIV infected patients.
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culture, ambiguity surrounding key data sharing 
concepts and terms, some of which we described 
in this paper. Perceptions about data sharing wob-
bled between pros and cons. For example, nega-
tive attitudes towards data sharing were expressed 
in mid-nineties: Glass was convinced that „no one 
would expect investigators to publish their raw 
data” (31). McCarthy argued that datasets should 
be available to both physicians and patients, while 
Warlow et al. argued that unlocking large datasets 
is neither reliable nor cheap (6,38). Gradually to-
wards the end of the century data sharing was in-
creasingly seen as a benefit, although practical 
solutions needed to be implemented to facilitate 
the practice. One possible explanation for this evo-
lution could be the newly founded Cochrane Col-
laboration, which promoted sharing of IPD and its 
use to conduct meta-analyses and also the cre-
ation of the concept of the EBM (23,26-28). 
To the best of our knowledge, this early stage of 
clinical trial data sharing has never been analyzed, 
so this paper might contribute to understanding 
of the process, with its systematic design as the 
most important strength.
The major limitation of our study is a lack of specif-
ic MESH terms for our scoping review. Further-
more, literature searches were performed only in 
Medline. In order to compensate for these limita-
tions, two librarians performed searches in-
dependently and we added references we discov-
ered through other related work.
Conclusions 
Throughout the last two decades of 20th century 
we observed glimpses and hints of attempts of CT 
data sharing and gradual emerging of the aware-
ness of risks and benefits related to data sharing. 
Multiple factors contributed to this evolution. Pub-
lic media and scientific journals played a signifi-
cant role in raising awareness and influencing the 
change of culture regarding CT data sharing. Vul-
nerable populations (cancer patients, AIDS pa-
tients, pregnant women, children, rare diseases, 
expensive therapies) frequently participated in 
breakthrough cases.
At the end of the century, the basis for further de-
velopment was laid and the year 2000 ends with 
initial trial registries, definition of datasets, the 
Cochrane Collaboration, enhanced systematic re-
views and emerging IPD meta-analysis, the use of 
evidence gained by IPD meta-analysis for develop-
ment of clinical guidelines and for making deci-
sions that would benefit patients, constant 
improvement of Internet features, all in the en-
vironment of the growing interest, pressure and 
discussion about the need for  data sharing by 
various constituencies. 
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